ABVC BioPharma Statistics
Total Valuation
ABVC BioPharma has a market cap or net worth of $6.42 million. The enterprise value is $8.95 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, before market open.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ABVC BioPharma has 12.24 million shares outstanding. The number of shares has increased by 187.47% in one year.
| Current Share Class | 12.24M |
| Shares Outstanding | 12.24M |
| Shares Change (YoY) | +187.47% |
| Shares Change (QoQ) | +9.57% |
| Owned by Insiders (%) | 22.76% |
| Owned by Institutions (%) | 1.86% |
| Float | 8.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.32 |
| Forward PS | n/a |
| PB Ratio | 0.75 |
| P/TBV Ratio | 0.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.56 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.34, with a Debt / Equity ratio of 0.34.
| Current Ratio | 0.34 |
| Quick Ratio | 0.05 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.77 |
Financial Efficiency
Return on equity (ROE) is -102.32% and return on invested capital (ROIC) is -33.19%.
| Return on Equity (ROE) | -102.32% |
| Return on Assets (ROA) | -25.30% |
| Return on Capital (ROIC) | -33.19% |
| Revenue Per Employee | $26,831 |
| Profits Per Employee | -$433,848 |
| Employee Count | 19 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ABVC BioPharma has paid $64,771 in taxes.
| Income Tax | 64,771 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.97% in the last 52 weeks. The beta is 0.75, so ABVC BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.75 |
| 52-Week Price Change | -55.97% |
| 50-Day Moving Average | 0.55 |
| 200-Day Moving Average | 0.80 |
| Relative Strength Index (RSI) | 49.63 |
| Average Volume (20 Days) | 372,903 |
Short Selling Information
The latest short interest is 252,971, so 2.07% of the outstanding shares have been sold short.
| Short Interest | 252,971 |
| Short Previous Month | 333,626 |
| Short % of Shares Out | 2.07% |
| Short % of Float | 2.88% |
| Short Ratio (days to cover) | 0.70 |
Income Statement
In the last 12 months, ABVC BioPharma had revenue of $509,788 and -$8.24 million in losses. Loss per share was -$0.82.
| Revenue | 509,788 |
| Gross Profit | 369,819 |
| Operating Income | -6.29M |
| Pretax Income | -12.37M |
| Net Income | -8.24M |
| EBITDA | -6.26M |
| EBIT | -6.29M |
| Loss Per Share | -$0.82 |
Full Income StatementBalance Sheet
The company has $208,153 in cash and $2.75 million in debt, giving a net cash position of -$2.54 million or -$0.21 per share.
| Cash & Cash Equivalents | 208,153 |
| Total Debt | 2.75M |
| Net Cash | -2.54M |
| Net Cash Per Share | -$0.21 |
| Equity (Book Value) | 7.98M |
| Book Value Per Share | 0.70 |
| Working Capital | -4.17M |
Full Balance SheetCash Flow
| Operating Cash Flow | -1.79M |
| Capital Expenditures | n/a |
| Free Cash Flow | -1.79M |
| FCF Per Share | -$0.15 |
Full Cash Flow StatementMargins
| Gross Margin | 72.54% |
| Operating Margin | -1,233.06% |
| Pretax Margin | -1,697.36% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |